Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 2—February 2010

Research

Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies1

Anthony T. NewallComments to Author , James G. Wood, Noemie Oudin, and C. Raina MacIntyre
Author affiliations: University of New South Wales, Sydney, New South Wales, Australia (A.T. Newall, J.G. Wood, C.R. MacIntyre); National Institute for Applied Sciences, Lyon, France (N. Oudin)

Main Article

Figure 1

Schematic of hybrid transmission and decision analytic economic model. [+] indicates a cloned subtree with the same structure as the branch above. In sensitivity analysis, the probabilities of healthcare utilization and death were independent of each other but dependent on the probability of clinical infection. We assumed those with serious complications would seek primary healthcare. SEIR, susceptible, exposed, infected, removed.

Figure 1. Schematic of hybrid transmission and decision analytic economic model. [+] indicates a cloned subtree with the same structure as the branch above. In sensitivity analysis, the probabilities of healthcare utilization and death were independent of each other but dependent on the probability of clinical infection. We assumed those with serious complications would seek primary healthcare. SEIR, susceptible, exposed, infected, removed.

Main Article

1This material was compiled before the declaration of pandemic (H1N1) 2009 and concerns stockpiling for a future influenza pandemic.

TOP